Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ADMA
ADMA BIOLOGICS, INC.
NASDAQ
$9.34
▼ DOWN 1.48% (-0.14)

KEY STATISTICS

Market Cap$2.16 B
52w High$20.46
52w Low$7.21
Dividend Yield—
Frequency—
P/E13.15
Volume1.84M
Shares Out.231.77M

COMPANY

LEADERSHIP

Adam S. Grossman
CHIEF EXECUTIVE
Adam S. Grossman

COMPENSATION 2026

Salary$925,000
Stock Awards$4,049,994
Incentive Plan Pay$1,156,250
All Other Comp.$56,084
Total$10,237,326

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 17, 2013
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
644

PRICE TARGET

Target High$21.00
Target Low$17.00
Target Median$18.00
Target Consensus$18.67

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$138.12M
NOV
4
WED

PRICE

$9.34 ▼ DOWN 1.48% (−$0.14)
$9.35$9.40$9.45$9.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.34

About ADMA Biologics, Inc.

https://www.admabiologics.com ↗

ADMA Biologics, Inc. develops, manufactures, and markets plasma-derived biologics for immune deficiencies and infectious diseases, including IVIG products and hepatitis B treatments, with a pipeline targeting infections like S. pneumonia.

INDUSTRY

Biotechnology

A PRODUCT ADMA BIOLOGICS, INC. IS KNOWN FOR

ASCENIV™ (Immune Globulin Intravenous, Human - slra)
ASCENIV™ (Immune Globulin Intravenous, Human - slra)

ASCENIV™ is an FDA-approved intravenous immune globulin (IVIG) for primary humoral immunodeficiency, serving as a key product driving ADMA Biologics' recent revenue growth.

COMPETITORS

COMPETITOR
BAX COMPARE
CSL COMPARE
GRFS COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ1-2024Q2-2024Q3-2024Q4-2024
ADMA BioManufacturing Segment$80.11M $106.18M ▲$113.09M ▲$116.42M ▲
Plasma Collection Centers Segment$1.78M $1.27M ▼$7.45M ▲$804K ▼
Corporate Segment$36K $36K $36K —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$133.98M $137.38M ▲$113.42M ▼$123.32M ▲
NonUS$246K $1.79M ▲$1.07M ▼$1.08M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
207
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.12% · 14.1M
FBT
3.16% · 10.0M
XBI
0.66% · 8.3M
VTI
0.00% · 7.1M
SCHA
0.05% · 1.1M
DFMC
0.10% · 837.3K
PSC
0.27% · 779.3K
XMWD.L
0.04% · 581.3K
LABU
0.45% · 301.2K
PSCH
1.10% · 217.3K
BBP
1.42% · 178.3K
AVSC
0.05% · 175.1K
FESM
0.02% · 135.0K
GSSC
0.10% · 117.7K
RSSL
0.07% · 110.1K
TMFS
1.43% · 89.7K
TQSM.TO
0.11% · 88.6K
ISMD
0.23% · 82.0K
BBSC
0.08% · 65.4K
JHSC
0.08% · 64.6K
FSCC
0.16% · 57.3K
TPSC
0.12% · 50.8K
AFTY
4.55% · 40.1K
EZM
0.04% · 35.4K
BFOR
0.14% · 34.4K
AI
AIMS
0.25% · 24.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.82%
HOLDERS
527
TOP 12 OF 527 · RANKED BY POSITION SIZE
Blackrock, Inc.
38.4M sh · $321.04M
Vanguard Group Inc
21.0M sh · $307.49M
Blackrock Inc.
18.6M sh · $208.45M
State Street Corp
17.1M sh · $143.26M
Invesco Ltd.
12.5M sh · $183.33M
Sachem Head Capital Management LP
11.4M sh · $207.48M
Capital Research Global Investors
11.2M sh · $100.83M
Rubric Capital Management LP
9.3M sh · $78.17M
First Trust Advisors LP
7.8M sh · $65.27M
Westfield Capital Management Co LP
7.0M sh · $127.55M
Nuveen, LLC
6.1M sh · $54.95M
Geode Capital Management, LLC
6.1M sh · $50.73M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings2
Price To Book2
Overall Score3

INSIDER TRADES

★
OFFICER: COO AND SVP, COMPLIANCE
Kestenberg-Messina Kaitlin M.
Sale · 3.2K shares
2026-07-24
★
OFFICER: CFO AND TREASURER
Kohler Terry
Purchase · 85.1K shares
2026-07-16
★
OFFICER: CFO AND TREASURER
Kohler Terry
Purchase · 136.4K shares
2026-07-16
★
DIRECTOR
Grossman Jerrold B
Purchase · 6.4K shares
2026-05-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
BUY 1
NEUTRAL 1
3 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM Canaccord Genuity BUY Cantor Fitzgerald NEUTRAL

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
BLTE$151.72COMPARE
MIRM$97.46COMPARE
LGND$280.49COMPARE
ACAD$29.11COMPARE
DYN$25.07COMPARE
TLX$11.29COMPARE